Abstract
Fragment-based lead generation (FBLG) has recently emerged as an alternative to traditional high throughput screening (HTS) to identify initial chemistry starting points for drug discovery programs. In comparison to HTS screening libraries, the screening sets for FBLG tend to contain orders of magnitude fewer compounds, and the compounds themselves are less structurally complex and have lower molecular weight. This report summarises the advent of FBLG within the industry and then describes the FBLG experience at AstraZeneca. We discuss (1) optimising the design of screening libraries, (2) hit detection methodologies, (3) evaluation of hit quality and use of ligand efficiency calculations, and (4) approaches to evolve fragment-based, low complexity hits towards drug-like leads. Furthermore, we exemplify our use of FBLG with case studies in the following drug discovery areas: antibacterial enzyme targets, GPCRs (melanocortin 4 receptor modulators), prostaglandin D2 synthase inhibitors, phosphatase inhibitors (protein tyrosine phosphotase 1B), and protease inhibitors (b-secretase).
Keywords: Fragment based lead generation, library design, high concentration screening, ligand efficiency, NMR, X-ray, BIAcore, MC4, PGDS, PTP1B
Current Topics in Medicinal Chemistry
Title: An Integrated Approach to Fragment-Based Lead Generation:Philosophy, Strategy and Case Studies from AstraZenecas Drug Discovery Programmes
Volume: 7 Issue: 16
Author(s): Jeffrey S. Albert, Niklas Blomberg, Alexander L. Breeze, Alastair J. H. Brown, Jeremy N. Burrows, Philip D. Edwards, Rutger H. A. Folmer, Stefan Geschwindner, Ed J. Griffen, Peter W. Kenny, Thorsten Nowak, Lise-Lotte Olsson, Hitesh Sanganee and Adam B. Shapiro
Affiliation:
Keywords: Fragment based lead generation, library design, high concentration screening, ligand efficiency, NMR, X-ray, BIAcore, MC4, PGDS, PTP1B
Abstract: Fragment-based lead generation (FBLG) has recently emerged as an alternative to traditional high throughput screening (HTS) to identify initial chemistry starting points for drug discovery programs. In comparison to HTS screening libraries, the screening sets for FBLG tend to contain orders of magnitude fewer compounds, and the compounds themselves are less structurally complex and have lower molecular weight. This report summarises the advent of FBLG within the industry and then describes the FBLG experience at AstraZeneca. We discuss (1) optimising the design of screening libraries, (2) hit detection methodologies, (3) evaluation of hit quality and use of ligand efficiency calculations, and (4) approaches to evolve fragment-based, low complexity hits towards drug-like leads. Furthermore, we exemplify our use of FBLG with case studies in the following drug discovery areas: antibacterial enzyme targets, GPCRs (melanocortin 4 receptor modulators), prostaglandin D2 synthase inhibitors, phosphatase inhibitors (protein tyrosine phosphotase 1B), and protease inhibitors (b-secretase).
Export Options
About this article
Cite this article as:
Albert S. Jeffrey, Blomberg Niklas, Breeze L. Alexander, Brown J. H. Alastair, Burrows N. Jeremy, Edwards D. Philip, Folmer H. A. Rutger, Geschwindner Stefan, Griffen J. Ed, Kenny W. Peter, Nowak Thorsten, Olsson Lise-Lotte, Sanganee Hitesh and Shapiro B. Adam, An Integrated Approach to Fragment-Based Lead Generation:Philosophy, Strategy and Case Studies from AstraZenecas Drug Discovery Programmes, Current Topics in Medicinal Chemistry 2007; 7 (16) . https://dx.doi.org/10.2174/156802607782341091
DOI https://dx.doi.org/10.2174/156802607782341091 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer’s Disease: A Systematic Review
Current Neuropharmacology Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Mechanisms of Tau Self-Aggregation and Neurotoxicity
Current Alzheimer Research Synthesis, Physico-Chemical Properties and DFT Calculations of New 2-(4- Arylpiperazine-1-yl)-1-(3-ethylbenzofuran-2-yl)ethanols As Potential Antihypertensive Agents
Current Organic Chemistry Preventive Antidepressant use in Patients with Hepatitis C Treated with Interferon-Alfa: a Systematic Review
Current Psychiatry Reviews Relationship between chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes and Alzheimer disease
CNS & Neurological Disorders - Drug Targets Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases
Current Pharmaceutical Design Identification of a Pathogenic PSEN1 Ala285Val Mutation Associated with Early-Onset Alzheimer’s Disease
Current Alzheimer Research The Use and Misuse of Exposure Therapy for Obsessive-Compulsive and Related Disorders
Current Psychiatry Reviews Chronic Hypoxia Potentiates Age-Related Oxidative Imbalance in Brain Vessels and Synaptosomes
Current Neurovascular Research The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology A Speech Recognition-based Solution for the Automatic Detection of Mild Cognitive Impairment from Spontaneous Speech
Current Alzheimer Research Epidemiology, Prognosis and Prevention of Non-Traumatic Intracerebral Hemorrhage
Current Pharmaceutical Design Chlorogenic Acid and Mental Diseases: From Chemistry to Medicine
Current Neuropharmacology Copper and Heme-Mediated Abeta Toxicity: Redox Chemistry, Abeta Oxidations and Anti-ROS Compounds
Current Topics in Medicinal Chemistry Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research The Peripheral Nervous System and the Pathogenesis of Prion Diseases
Current Molecular Medicine SUBJECT INDEX
Current Neuropharmacology Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry Astrocytes: From the Physiology to the Disease
Current Alzheimer Research